Lime Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Lime Therapeutics's estimated annual revenue is currently $930k per year.
- Lime Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Lime Therapeutics has 6 Employees.
- Lime Therapeutics grew their employee count by 50% last year.
Lime Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and CTO | Reveal Email/Phone |
2 | Research Associate | Reveal Email/Phone |
3 | Scientist | Reveal Email/Phone |
4 | First Hire - Lead Scientist | Reveal Email/Phone |
Lime Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Lime Therapeutics?
Lime Therapeutics is the lipids company. \n\nWe reversing lysosomal lipid dysfunction due to aging, environment, and genetic mutations in cancer and cardiometabolic disorders. We have developed a first-of-its-kind real-time lipid-detection platform, LipidSense™, to identify new targets and screen for novel drug candidates.\n\nIn addition to our internal cancer drug discovery efforts, we have a partnership with Novo Nordisk in the field of atherosclerosis. In the future, Lime will expand its therapeutic development efforts in neurodegeneration, liver disease, and lysosomal storage disorders.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 6 | -40% | N/A |
#2 | $0.6M | 6 | -14% | N/A |
#3 | $0.4M | 6 | -14% | N/A |
#4 | $0.4M | 6 | -45% | N/A |
#5 | $0.2M | 6 | 0% | $7.9M |